DCM
ORIC icon

Defilade Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Defilade Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
1,047,690
+204,762
+24% +$1.86M 1.52% 26
2026
Q1 		$10.7M Buy
+842,928
New +$9.57M 1.5% 29

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defilade Capital Management's ORIC Position: Q2 2026 in Review

Defilade Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 24% in Q2 2026, buying an estimated $1.86M and bringing the position to 1,047,690 shares worth $11.3M. The position accounts for 1.52% of the portfolio, ranked #26.

Defilade Capital Management first reported a position in ORIC in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Defilade Capital Management held 1,047,690 shares of Oric Pharmaceuticals worth $11.3M as of Q2 2026.
  • Defilade Capital Management bought 204,762 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
  • Oric Pharmaceuticals made up 1.52% of Defilade Capital Management's portfolio in Q2 2026, its #26 holding.
  • Defilade Capital Management first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.